CN1165537C - 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚 - Google Patents

作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚 Download PDF

Info

Publication number
CN1165537C
CN1165537C CNB998128341A CN99812834A CN1165537C CN 1165537 C CN1165537 C CN 1165537C CN B998128341 A CNB998128341 A CN B998128341A CN 99812834 A CN99812834 A CN 99812834A CN 1165537 C CN1165537 C CN 1165537C
Authority
CN
China
Prior art keywords
dihydro
pyrrolo
hydrogen
indol
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998128341A
Other languages
English (en)
Chinese (zh)
Other versions
CN1325399A (zh
Inventor
D��R���ǵ�˹
D·R·亚当斯
J·M·本特利
A
J·R·A·罗菲
��������ķ������
R·J·哈姆利恩
S·戈尔
J���ض�
M·A·J·敦顿
P����άѷ
J·E·P·戴维逊
M·J·比克尔迪克
I·A·克利菲
I
H·L·曼瑟尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Publication of CN1325399A publication Critical patent/CN1325399A/zh
Application granted granted Critical
Publication of CN1165537C publication Critical patent/CN1165537C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB998128341A 1998-09-01 1999-09-01 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚 Expired - Fee Related CN1165537C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9819035.8A GB9819035D0 (en) 1998-09-01 1998-09-01 Chemical compounds VII
GB9819035.8 1998-09-01

Publications (2)

Publication Number Publication Date
CN1325399A CN1325399A (zh) 2001-12-05
CN1165537C true CN1165537C (zh) 2004-09-08

Family

ID=10838167

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998128341A Expired - Fee Related CN1165537C (zh) 1998-09-01 1999-09-01 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚

Country Status (29)

Country Link
US (1) US6433175B1 (enExample)
EP (1) EP1109813B1 (enExample)
JP (1) JP2002523508A (enExample)
KR (2) KR100768595B1 (enExample)
CN (1) CN1165537C (enExample)
AT (1) ATE273308T1 (enExample)
AU (1) AU758084B2 (enExample)
BR (1) BR9913477A (enExample)
CA (1) CA2341991C (enExample)
CZ (1) CZ296275B6 (enExample)
DE (1) DE69919364T2 (enExample)
DK (1) DK1109813T3 (enExample)
ES (1) ES2226430T3 (enExample)
GB (1) GB9819035D0 (enExample)
HR (1) HRP20010126B1 (enExample)
HU (1) HUP0103333A3 (enExample)
ID (1) ID28842A (enExample)
IL (2) IL141659A0 (enExample)
MX (1) MXPA01002101A (enExample)
NO (1) NO321527B1 (enExample)
NZ (1) NZ510097A (enExample)
PL (1) PL346427A1 (enExample)
PT (1) PT1109813E (enExample)
RU (1) RU2232162C2 (enExample)
SI (1) SI1109813T1 (enExample)
TR (2) TR200100659T2 (enExample)
WO (1) WO2000012510A1 (enExample)
YU (1) YU16001A (enExample)
ZA (1) ZA200101457B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
US6818639B2 (en) 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット（プブリクト） セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
EP1343768A1 (en) 2000-12-20 2003-09-17 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
CN1250549C (zh) * 2000-12-27 2006-04-12 霍夫曼-拉罗奇有限公司 吲哚衍生物及其作为5－ht2b和5－ht2c受体配体的应用
WO2002098400A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
JP2004532887A (ja) 2001-06-01 2004-10-28 アルコン，インコーポレイテッド 新規な融合インダゾールおよびインドールおよび緑内障治療へのこれらの使用
MXPA03010807A (es) 2001-06-01 2004-11-22 Alcon Inc Piranoidazoles y su uso para el tratamiento del glaucoma.
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
NZ536664A (en) 2002-06-19 2007-07-27 Biovitrum Ab Piperazinylpyrazine derivative compounds, their use and preparation
CN1678302A (zh) * 2002-08-30 2005-10-05 爱尔康公司 取代的5－苯并二氢吡喃－5－基－乙胺化合物及其在治疗青光眼中的用途
WO2004054572A2 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US7608626B2 (en) 2004-11-01 2009-10-27 Wyeth Substituted indolizines and derivatives as CNS agents
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
MX2007012082A (es) 2005-03-31 2007-11-20 Pfizer Prod Inc Derivados de ciclopentapiridina y tetrahidroquinolina.
FR2884252B1 (fr) * 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
WO2006116218A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
CN101171252B (zh) * 2005-05-03 2011-06-01 霍夫曼-拉罗奇有限公司 作为5-ht2配体的四环氮杂吡嗪并二氢吲哚类化合物
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
EP2044029B1 (en) * 2006-07-14 2011-01-26 Pfizer Products Inc. Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CN102964352B (zh) * 2012-11-23 2015-04-08 华中师范大学 具有生物活性的手性2,3-二氢吡咯[1,2-a]吲哚衍生物及其不对称合成方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
EP3860996A4 (en) 2018-10-02 2022-08-31 Northwestern University BETA-CARBOLINES AS POSITIVE ALLOSTERIC MODULATORS OF HUMAN SEROTONIN RECEPTOR 2C (5-HT2C)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250783A (en) * 1964-09-21 1966-05-10 American Cyanamid Co Novel pyrrolo (1, 2-alpha) indoles
US4134894A (en) * 1978-05-04 1979-01-16 Warner-Lambert Company Pyrrolo[1,2-a]indole compounds
GB8416724D0 (en) * 1984-06-30 1984-08-01 Sorbio Sa Lab Active compounds
US4778812A (en) * 1987-06-12 1988-10-18 American Home Products Corporation 2,3-dihydro-9-methyl-1H-pyrrolo[1,2-a]indol-1-amines and derivatives thereof
GB8802127D0 (en) * 1988-02-01 1988-03-02 Glaxo Group Ltd Chemical compounds
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
DE69325167T2 (de) * 1992-03-12 2000-01-20 Smithkline Beecham P.L.C., Brentford Kondensierte indol-derivate als 5-ht4-rezeptor-antagonisten
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW251284B (enExample) * 1992-11-02 1995-07-11 Pfizer
EP0688216A1 (en) * 1993-03-08 1995-12-27 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating or preventing cerebrovascular diseases
US5629427A (en) * 1993-08-26 1997-05-13 Peterson; Dwight M. 2,7-diaminomitosene analogues

Also Published As

Publication number Publication date
KR100768595B1 (ko) 2007-10-18
ES2226430T3 (es) 2005-03-16
ID28842A (id) 2001-07-05
GB9819035D0 (en) 1998-10-28
HUP0103333A2 (hu) 2002-01-28
HUP0103333A3 (en) 2002-07-29
BR9913477A (pt) 2001-10-09
PT1109813E (pt) 2004-11-30
AU5637599A (en) 2000-03-21
KR20010079715A (ko) 2001-08-22
EP1109813A1 (en) 2001-06-27
WO2000012510A1 (en) 2000-03-09
RU2232162C2 (ru) 2004-07-10
NZ510097A (en) 2003-06-30
TR200100659T2 (tr) 2001-10-22
YU16001A (sh) 2003-10-31
PL346427A1 (en) 2002-02-11
DE69919364T2 (de) 2005-08-04
TR200501110T2 (tr) 2005-07-21
AU758084B2 (en) 2003-03-13
CA2341991A1 (en) 2000-03-09
SI1109813T1 (en) 2005-02-28
NO321527B1 (no) 2006-05-15
HRP20010126A2 (en) 2002-02-28
KR20070062609A (ko) 2007-06-15
NO20010991L (no) 2001-04-23
CN1325399A (zh) 2001-12-05
ZA200101457B (en) 2002-02-21
ATE273308T1 (de) 2004-08-15
CZ2001772A3 (cs) 2001-07-11
IL141659A (en) 2007-10-31
NO20010991D0 (no) 2001-02-27
JP2002523508A (ja) 2002-07-30
US6433175B1 (en) 2002-08-13
EP1109813B1 (en) 2004-08-11
DK1109813T3 (da) 2004-12-20
CA2341991C (en) 2009-04-07
IL141659A0 (en) 2002-03-10
DE69919364D1 (de) 2004-09-16
MXPA01002101A (es) 2002-08-20
HK1034967A1 (en) 2001-11-09
HRP20010126B1 (en) 2005-06-30
CZ296275B6 (cs) 2006-02-15

Similar Documents

Publication Publication Date Title
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CN1289499C (zh) 吡嗪并(氮杂)吲哚衍生物
CN1187330C (zh) 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用
CN1277828C (zh) 哌嗪衍生物
CN100351236C (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚衍生物，其制备方法和用途
CN1167681C (zh) 稠合二氢吲哚衍生物及其作为5ht特别是5ht2c受体配体的用途
CN1240701C (zh) 用作5HT2C激动剂的2,3,4,4a－四氢－1H－吡嗪并(1,2－a)喹喔啉－5(6H)酮衍生物
CN1281608C (zh) 新氮杂－吲哚基衍生物
CN1051313C (zh) 5－芳基吲哚衍生物及其用途、含有它们的药物组合物以及制备它们的中间体
CN1128788C (zh) 苄基(亚苄基)－内酰胺衍生物,它们的制备以及作为5－ht1a和/或5－ht1d受体的选择性拮抗剂(激动剂)的用途
CN1034865C (zh) 2-氨基嘧啶酮的制备方法
CN1118598A (zh) 吡咯并吡啶衍生物
CN1361779A (zh) 新化合物
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN1933834A (zh) 吲唑甲酰胺衍生物在制备用于治疗和预防疟疾的药物中的用途
CN1553910A (zh) 作为5-羟色胺-6配基的杂环基-吲唑或氮杂吲唑化合物
CN1426411A (zh) 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
CN1630636A (zh) 二氢吲哚衍生物及其作为5－ht2受体配体的用途
CN1451007A (zh) 腺苷A2a受体拮抗剂
CN1209129A (zh) 促性腺激素释放激素的拮抗药
CN1668620A (zh) 用于5－羟色胺－6配体的1－杂环基烷基－3－磺酰基氮杂吲哚或－氮杂吲唑衍生物
CN1491225A (zh) 三杂环化合物和包括其作为活性组分的药物
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1344257A (zh) cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
CN1245405C (zh) 哌嗪衍生物

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040908

Termination date: 20091009